BRAF and metastatic melanoma: The triple therapy combination of dabrafenib (BRAF inhibitor), trametinib (MEK inhibitor), and pembrolizumab (anti PD-1 antibody) were administered to patients with advanced BRAFV600-mutated metastatic melanoma [73].